

Roche: MetMAB Phase III Trial in 2nd-/3rd-Line NSCLC Discontinued Early Due to Lack of Efficacy; Negative Read-Through for Ongoing 1st-Line Study

MetMAB fails to show clinical benefit based on pre-specified interim analysis. Roche announced this morning (3/3) that MetMAB (onartuzumab)'s Phase III trials (MetLung) in previously treated NSCLC (2nd-/3rd-line) was discontinued early due to the lack of clinically meaningful benefit during an interim analysis. The trial was being evaluated in combination with Tarceva vs. Tarceva monotherapy in NSCLC patients who screened positively for the MET protein (MET high).

Roche highlighted that the company is currently evaluating the implications of the MetLung data across the ongoing Phase III trials in 1st-line NSCLC. However, we believe that **today's failure is likely to have a negative read across to these ongoing trials.**

We had risk-adjusted peak sales opportunity of SFr1.0bn for the previously treated lung cancer indication. We were forecasting un-adjusted global peak sales estimates of \$1.4bn (SFr1.3bn) for MetMAB in the NSCLC indication. We had applied a 70% probability of success which contributed SFr2.0 per share (1%) to our EmV. Company compiled post 3Q13 consensus was modeling MetMAB sales of SFr389m by 2017 (vs JPM of SFr168m).

Next catalyst: 1) PD-L1 data presentation in new tumor in mid 2014 2) PD-L1 data presentation at ASCO in mid 2014 3) Cobimetinib Phase III data in melanoma in mid 2014 4) Kadcyla in 1st line breast cancer (MARIANNE data) in 2H14.

Source: JPMorgan/Vosser, March 3, 2014

Oncology Indication: Lung

Keyword: Clinical Trials/Pipeline